Catamaran Bio, Bio-Techne expand CAR-NK cell collaboration

By The Science Advisory Board staff writers

Catamaran Bio and Bio-Techne have expanded their collaboration on the development of cell engineering and cell process technologies for Catamaran's manufacturing of chimeric antigen receptor-natural killer (CAR-NK) cell therapies.

Under the collaboration, Bio-Techne will contribute its cell expansion technologies and both companies will contribute expertise to enable large-scale production of functional CAR-NK cells.

Catamaran now has license to Bio-Techne's rights related to the TcBuster transposon system for use in the manufacturing of allogenic cell therapies; it has integrated this system into its CAR-NK Tailwind platform.

The two firms' collaboration began in 2020, they said.

Financial details of the agreement were not disclosed.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking